More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Diabetes spending growth is projected to exceed 10% in both developed and emerging markets over the next five years, driven by innovative new therapies and greater diagnosis rates.  The diabetes market is projected to see a major influx of new...
DCAT Value Chain Insights

Specialty medicines are an important engine of growth for the global pharmaceutical market, projected to account for 40% of the market by 2018. So what are the leading therapeutic classes and key drugs in these classes? DCAT Value Chain Insights...
DCAT Value Chain Insights

A recent study by the Tufts Center for the Study of Drug Development estimates the cost of developing a new drug at nearly $2.6 billion. So what is the cost for new drug development?  A recent study by the Tufts Center for the Study of Drug...
DCAT Value Chain Insights

The Lilly MDR-TB Partnership, a public-private partnership set up by Eli Lilly to address the problem of multidrug-resistant tuberculosis (MDR-TB), is a successful example of a global health initiative involving technology transfer and...
DCAT Value Chain Insights

The decision last week by Sanofi's board of directors to remove Sanofi CEO Christopher A. Viehbacher spells a major change for the company. As interim CEO Serge Weinberg takes the helm of the company, DCAT Value Chain Insights (VCI) takes an inside...
DCAT Value Chain Insights

GlaxoSmithKline fine-tunes its strategies with an incremental restructuring plan and a possible initial public offering of its interest in the specialtist HIV company, Viiv Healthcare. GlaxoSmithKline (GSK) has announced a new restructuring plan...